191 related articles for article (PubMed ID: 10419700)
1. A prognostic table to guide practitioners advising patients on adjuvant systemic therapy in early breast cancer.
Stotter A
Eur J Surg Oncol; 1999 Aug; 25(4):341-3. PubMed ID: 10419700
[No Abstract] [Full Text] [Related]
2. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
3. Revised prognostic table to guide practitioners advising patients on adjuvant systematic therapy in early breast cancer.
Stotter A
Eur J Surg Oncol; 2007 Dec; 33(10):1211-2. PubMed ID: 17399937
[No Abstract] [Full Text] [Related]
4. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
5. [Recent advance in adjuvant therapy for breast cancer].
Shimizu C; Watanabe T
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of adjuvant therapy for patients with early-stage (I-IIa) breast cancer].
Semiglazov VF
Vopr Onkol; 1998; 44(2):137-41. PubMed ID: 9615814
[No Abstract] [Full Text] [Related]
7. Systemic adjuvant therapy for breast cancer.
Reed EC
Nebr Med J; 1996 Mar; 81(3):48-50. PubMed ID: 8907820
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
9. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
[TBL] [Abstract][Full Text] [Related]
10. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
11. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
Jiang Z; Song S; Liu X
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of adjuvant systemic therapy in organ preserving treatment of pT1-2N0M0 breast cancer].
Semiglazov VF; Kanaev SV; Bugrova IL; Vlasov AN
Vopr Onkol; 1999; 45(5):516-9. PubMed ID: 10629708
[TBL] [Abstract][Full Text] [Related]
13. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
14. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology].
Bontenbal M; Nortier JW; Beex LV; Bakker P; Hupperets PS; Nooij MA; van Veelen H; Vreugdenhil G; Richel DJ; Blijham GH
Ned Tijdschr Geneeskd; 2000 May; 144(21):984-9. PubMed ID: 10858788
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
[TBL] [Abstract][Full Text] [Related]
17. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
18. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer].
Dryzhak VI
Vopr Onkol; 1989; 35(7):771-8. PubMed ID: 2528239
[No Abstract] [Full Text] [Related]
19. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
20. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
